retroviral vector-transduced autologous t cells expressing anti-GPC3 CARs

Retroviral vector-transduced autologous T cells expressing anti-GPC3 chimeric antigen receptors (CARs) are a form of personalized cell therapy in which a patient's own T lymphocytes are collected, genetically modified ex vivo using a retroviral vector to express a synthetic receptor targeting glypican-3 (GPC3), and then reinfused into the patient. GPC3 is an oncofetal protein highly expressed on the surface of hepatocellular carcinoma (HCC) and some other solid tumors but not in normal adult tissues. The engineered CAR enables the T cells to specifically recognize and kill GPC3-expressing tumor cells. This approach represents an immunotherapy strategy designed for advanced, unresectable HCC that has failed standard treatments[1][2][4]. The mechanism involves direct cytotoxicity against tumor cells via recognition of GPC3 by the introduced CAR, leading to activation, proliferation, and effector function of the modified T-cells.

Other names

anti-GPC3 CAR-T cellsanti-GPC-3 CAR-T cellsanti-GPC 3 CAR-T cellsGPC3-targeted CAR-T cellsGPC-3-targeted CAR-T cellsGPC 3-targeted CAR-T cellsGlypican-3 targeted chimeric antigen receptor T-cellsGlypican3 targeted chimeric antigen receptor T-cellsGlypican 3 targeted chimeric antigen receptor T-cells